# A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer

> **NCT06609005** · PHASE1,PHASE2 · RECRUITING · sponsor: **Shenzhen Ionova Life Sciences Co., Ltd.** · enrollment: 84 (estimated)

## Conditions studied

- Advanced Metastatic Castration Resistant Prostate Cancer

## Interventions

- **DRUG:** INV-9956

## Key facts

- **NCT ID:** NCT06609005
- **Lead sponsor:** Shenzhen Ionova Life Sciences Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-23
- **Primary completion:** 2026-04-17
- **Final completion:** 2028-01-17
- **Target enrollment:** 84 (ESTIMATED)
- **Last updated:** 2025-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06609005

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06609005, "A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT06609005. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*